There’s a dynamic shift taking place in preventive medicine. When paired correctly with core diagnostics and imaging, current advances in genome sequencing and artificial intelligence have the potential to move us away from reactive medicine and illness and toward preventative care and wellness. This transformation can improve patient outcomes and drastically reduce costs on overburdened health care systems, but I believe a traditionalist approach threatens to stall progress unless innovation is embraced. One answer lies in understanding the importance of preventive medicine, and three elements critical to its success: genomics, imaging, and core diagnostics.
For too long, medical care and diagnostics have remained focused on addressing patients’ symptoms once they develop, performing “reactive medicine.” These interventions can prolong or improve an already sick or dying person’s life, but this process is often one of trial and error riddled with side effects and hefty medical bills.
Reactive medicine isn’t just bad for patients—it’s bad for our economy. According to a report from the CMS Office of the Actuary, health care spending in the U.S. grew to $4.3 trillion in 2021, while spending on vaccinations and disease prevention dropped by 5.2% to $212.1 billion. The trend has long been to increase investment in medical treatment rather than prevention, despite the fact that it inflates spending while often failing to improve quality of life or human lifespan.
As an economist, my first instinct is always to investigate the underlying value mechanics of the problems we face, and the U.S. health care system poses a tricky problem: How can we protect lives and improve health outcomes for our communities while remaining cost-effective? I believe the key lever to efficient health care is to get ahead of disease rather than chasing symptoms and concentrating on costly treatments. In my opinion, our future lies in the widespread adoption of preventive precision medicine.
Genomics research now makes it possible to identify and treat conditions in their earliest stages, often eliminating the need for treatment later. This approach can save billions of dollars in patient care, while also saving millions of lives.
PREVENTIVE CARE WITH GENOMICS AND AI
Proper preventive care starts with early detection. In the United States, heart disease and cancer are the two leading causes of death, and too many deaths occur due to a failure to detect risk and treat illness preventively. However, today’s clinical genomic testing can provide life-saving answers, helping us catch these diseases earlier.
Using a blood test, samples can be analyzed for all genes associated with clinical conditions, detecting cancers that may not be found through conventional screening techniques, and searching for patterns that detect a predisposition for chronic diseases. Genomic testing is an excellent way to identify hereditary risks and unearth insights about cancers, cardiovascular disease, and metabolic conditions.
Early detection can significantly increase life expectancy. Research shows that early detection of breast cancer has a 99% survival rate as opposed to a 29% survival rate for breast cancer that has progressed throughout the body. Similarly, 20% of U.S. deaths are due to heart disease, but there is potential to shrink this number—coronary disease has already declined and may be reduced by 27% by 2030.
Genomic testing can also reveal predispositions for conditions such as familial hypercholesterolemia, a genetic disorder affecting one million Americans that increases the risk of death from heart attacks and stroke. FH is underdiagnosed and undertreated, but genomics can identify FH risk early and promote personalized preventive care to control cholesterol.
Because genomic data is dense, these test results are best analyzed with AI. Machine learning, a subset of AI, recognizes patterns as it processes genomic data, essentially “learning” to provide more accurate predictions of diagnostic outcomes. Since the amount of genomic data found in a single person is so vast, AI helps to identify patterns that may not otherwise be obvious. Using genetic testing and AI to detect potential diseases early can make it easier to take preventive action.
THE ROLE OF IMAGING
While genomic testing is a very good way to detect early-stage tumors, MRIs can help complete the picture by providing a high-resolution image of everything inside the body. MRIs reveal spinal issues, tumors, brain volume changes, muscular and joint degeneration, and crucial ongoing information about organ health.
Annual full-body imaging is one of the most important tools at our disposal for preventive care, yet it is currently too expensive for most patients to access; most insurance plans do not cover preventive imaging. However, full-body imaging—like genetic testing—has the potential to save our country billions in health care costs. I believe we must shift from outdated reactive medicine to innovative proactive efforts.
CORE DIAGNOSTICS
Core diagnostics provide key health information most providers already gather at routine health appointments. However, according to the University of Chicago, about 40% of patients report skipping a routine test or appointment, an issue that has been exacerbated by the COVID-19 pandemic. This failure to collect ongoing health information from patients on lifestyle and environmental factors that may be impacting health—or regularly assess cholesterol levels, blood pressure, heart rate, weight, and BMI—is preventing the ability to transition toward preventive care.
Technological advancements may once again provide a solution. Innovations in cloud computing make sharing diagnostic data easier so that patients can more quickly access their own data. User-friendly dashboards and virtual check-ins are increasingly common, empowering patients to become more proactive about care.
As more patients and providers adopt preventive care, the body of diagnostic information will grow, making it easier for physicians to prescribe more effective preventions and treatments based on genetic characteristics. By combining regular core diagnostic work-ups with more robust imaging, genomic testing, and data powered by AI, cancers and diseases can be addressed before they become fatal threats.
Jo Bhakdi is an entrepreneur, economist, innovator, and the founder and CEO of Quantgene.